Clinical sensitivity is higher for HIV-positive (HIV+) TB patients with low CD4 counts, so the Alere LF-LAM has been proposed as a complement to the Xpert for immunocompromised HIV+ individuals, potentially compensating for the poorer performance of Xpert in this population [22]. This evidence concerns the gene CD4 and tuberculosis.